Home / Pharmaceutical / Competitor Analysis ErbB / Her Receptor Antagonists

Competitor Analysis ErbB / Her Receptor Antagonists

Published: Mar 2015 | No Of Pages: 168 | Published By: La Merie Publishing
The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
 
Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody  therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.
 
The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities. 
 
Competitor projects are listed in a tabular format providing information on:
 
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
 
About Competitor Analysis Series:
 
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
  • Sales of Small Molecules Inhibitors of the ErbB/Her Receptor Family
  • Sales of Antibodies Targeting ErbB/Her Receptors
 
1) Small Molecules Targeting the ErbB/Her Receptor Family
 
a) Selective EGF-R Tyrosine Kinase (TK) Inhibitors
  • Tarceva Pipeline
  • Iressa Pipeline
  • Pipeline of Other EGF-R Selective TK Inhibitors
 
b) Selective Her2 (ErbB2) TK Inhibitors
 
c) Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
 
  • Tykerb  Pipeline
  • Pipeline of Other Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
 
d) Pan-Her (EGF-R, Her2 and Her4) / pan-Erb (ErbB1, ErbB2, ErbB4) TK Inhibitors
 
  • Gilotrif Pipeline
  • Neratinib Pipeline
  • Dacomitinb Pipeline
  • Poziotinib Pipeline
  • Pipeline of Other Pan-Her Tk Inhibitors
 
e) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) Inhibition
 
f) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) and Her2 (ErbB2) Inhibition
 
2) Biologics (Cells, Proteins, RNA) Targeting the ErbB/Her Receptor Family
 
3) Vaccines Targeting the ErbB/Her Receptor Family
 
a) EGF-R (ErbB1) Vaccines
b) Her2 (ErbB2) Vaccines
c) Her3 (ErbB3) Vaccines
 
4) Antibodies Targeting the ErbB/Her Receptor Family
 
a) Selective EGF-R (ErbB1) Antibodies
 
  • Erbitux Pipeline
  • Vectibix Pipeline
  • Nimotuzumab Pipeline
  • Pipeline of Other Selective EGF-R (ErbB1) Antibodies
  • Biosimilar Cetuximab Pipeline
  • Biosimilar Panitumumab Pipeline
 
b) Selective Her2 (ErbB2) Antibodies
 
  • Herceptin Pipeline
  • Perjeta Pipeline
  • Kadcyla Pipeline
  • Pipeline of Other Selective Her2 (ErbB2) Antibodies
  • Biosimilar Trastuzumab Pipeline
 
c) Selective Her3 (ErbB3) Antibodies
 
d) Dual and Pan ErbB / Her Antibodies
 
e) Dual Target Antibodies incl. ErbB/Her Receptor Antagonism
 
5) Corporate ErbB/Her Receptor Antagonist R&D Pipelines
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +